Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support

Stock Track

07/06

SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.

The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.

Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1171774118"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171774118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171774118?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171774118","market":"sg","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support","media":"Stock Track","content":"<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-06 09:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"","article_id":"1171774118","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171774118","pubTimestamp":1783302443,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票轨迹|SBP集团盘中大涨5.49%药物管线进展及政策利好支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}